Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Chen, Yunzhen ^a   Liu, Haichun ^a   Wu, Wenliang ^a   Li, Yi ^a   Li, Jianmin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bone metastasis; Genetic variants; Non small cell lung cancer; Osteopontin

Indexed keywords

OSTEOPONTIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 84880346619     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-45     Document Type: Article

References (31)

1. Lower blood calcium associates with unfavorable prognosis and predicts for bone metastasis in NSCLC. Shen H, Li Y, Liao Y, Zhang T, Liu Q, Du J, PLoS One 2012 7 34264 10.1371/journal.pone.0034264 22479582
2. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L, Clin Canc Res: an official journal of the American Association for Cancer Research 2010 16 2383 2390 10.1158/1078-0432. CCR-09-2793
3. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Gandara D, Narayan S, Lara PN Jr, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S, Clin Canc Res: an official journal of the American Association for Cancer Research 2005 11 5057s 5062s 10.1158/1078-0432.CCR-05-9012
4. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA, Clin Lung Canc 2006 8 195 202 10.3816/CLC.2006.n.047
5. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Liu SK, Olive PL, Bristow RG, Cancer Metastasis Rev 2008 27 445 458 10.1007/s10555-008-9137-8 18516501
6. Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. Hashisako M, Wakamatsu K, Ikegame S, Kumazoe H, Nagata N, Kajiki A, Tohoku J Exp Med 2012 228 163 168 10.1620/tjem.228.163 23036980
7. A novel 3-D mineralized tumor model to study breast cancer bone metastasis. Pathi SP, Kowalczewski C, Tadipatri R, Fischbach C, PLoS One 2010 5 8849 10.1371/journal.pone.0008849 20107512
8. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, et al. PLoS One 2011 6 19234 10.1371/journal.pone.0019234 21559440
9. Clinical features of metastatic bone disease and risk of skeletal morbidity. Coleman RE, Clin Canc Res: an official journal of the American Association for Cancer Research 2006 12 6243s 6249s 10.1158/1078-0432.CCR-06- 0931
10. Bone metastasis: pathogenesis and therapeutic implications. Clezardin P, Teti A, Clin Exp Metastasis 2007 24 599 608 10.1007/s10585-007-9112-8 18008175
11. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC, Spencer MJ, J Clin Invest 2009 119 1583 1594 10.1172/JCI37662 19451692
12. Expression and clinical significance of osteopontin in calcified breast tissue. Huan JL, Xing L, Qin XJ, Gao ZG, Pan XF, Zhao ZD, Asian Pac J Cancer Prev 2012 13 5219 5223 10.7314/APJCP.2012.13.10.5219 23244138
13. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Senger DR, Perruzzi CA, Cancer Res 1985 45 5818 5823 4053052
14. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN, Int J Biochem Cell Biol 2008 40 2303 2314 10.1016/j.biocel.2008.03.020 18490187
15. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Staal A, van Wijnen AJ, Birkenhager JC, Pols HA, Prahl J, DeLuca H, Gaub MP, Lian JB, Stein GS, van Leeuwen JP, Stein JL, Mol Endocrinol 1996 10 1444 1456 10.1210/me.10.11.1444 8923469
16. Expressions of Osteopontin (OPN), alphanubeta3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC). Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, Shao CK, Chin J Cancer Res 2012 24 103 108 10.1007/s11670-012-0103-1 23359766
17. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Chung JH, Park MS, Kim YS, Chang J, Kim JH, Kim SK, Yonsei Med J 2005 46 388 393 10.3349/ymj.2005.46.3.388 15988811
18. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E, Br J Cancer 1997 76 760 764 10.1038/bjc.1997.458 9310242
19. Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G, BMC Cancer 2012 12 477 10.1186/1471-2407-12-477 23072570
20. The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, Kao SY, Oral Oncol 2010 46 302 306 10.1016/j.oraloncology.2010.01. 018 20219412
21. The role of osteopontin in tumor progression and metastasis in breast cancer. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H, Canc Epidemiol Biomarkers Prev 2007 16 1087 1097 10.1158/1055-9965.EPI-06-1008
22. The role of osteopontin in tumor metastasis. Wai PY, Kuo PC, J Surg Res 2004 121 228 241 10.1016/j.jss.2004.03.028 15501463
23. Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW, Cell Motil Cytoskeleton 1999 43 269 287 10.1002/(SICI)1097- 0169(1999)43:4<269::AID-CM1>3.0.CO;2-5 10423269
24. Elevated serum osteopontin levels and genetic polymorphisms of osteopontin are associated with Vogt-Koyanagi-Harada disease. Chu M, Yang P, Hu R, Hou S, Li F, Chen Y, Kijlstra A, Invest Ophthalmol Vis Sci 2011 52 7084 7089 10.1167/iovs.11-7539 21810982
25. Osteopontin: an early innate immune marker of Escherichia coli mastitis harbors genetic polymorphisms with possible links with resistance to mastitis. Alain K, Karrow NA, Thibault C, St-Pierre J, Lessard M, Bissonnette N, BMC Genom 2009 10 444 10.1186/1471-2164-10-444
26. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K, J Neuroimmunol 2003 136 125 129 10.1016/S0165-5728(03)00004-3 12620651
27. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT, Gut 2007 56 782 789 10.1136/gut.2006.109868 17148500
28. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Lung Canc 2007 57 373 380 10.1016/j.lungcan.2007.04.005
29. Osteopontin expression and distribution in human carcinomas. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR, Am J Pathol 1994 145 610 623 8080043
30. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M, Mol Carcinog 2009 48 14 23 10.1002/mc.20452 18459127
31. Thirteen single-nucleotide polymorphisms in the human osteopontin gene identified by sequencing of the entire gene in Japanese individuals. Iwasaki H, Shinohara Y, Ezura Y, Ishida R, Kodaira M, Kajita M, Nakajima T, Shiba T, Emi M, J Hum Genet 2001 46 544 546 10.1007/s100380170037 11558904